Stockscreener 앱 받기
1.0355
0.00%
0.0055
전일 마감가:
$1.03
열려 있는:
$1.04
하루 거래량:
155.39K
Relative Volume:
0.03
시가총액:
$13.94M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0677
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+4.40%
1개월 성능:
+25.60%
6개월 성능:
-57.79%
1년 성능:
-79.48%
1일 변동 폭
$1.03
$1.0896
1주일 범위
$0.9374
$1.0896
52주 변동 폭
$0.3975
$5.44
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
1.03 | 13.94M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.09 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.05 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.78 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.26 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.39 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin - marketscreener.com
Moleculin secures two new US patents for cancer drug Annamycin By Investing.com - Investing.com India
Moleculin Biotech Secures Two New U.S. Patents - TipRanks
Moleculin secures two new US patents for cancer drug Annamycin - Investing.com Australia
Moleculin Biotech (MBRX) Secures New Patents for Annamycin Innovation | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents - GlobeNewswire
Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Moleculin Biotech (MBRX) Reveals Promising Data for Annamycin at - GuruFocus
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstr - GuruFocus
Moleculin Biotech Unveils Promising Annamycin Data at AACR - TipRanks
Moleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer Therapies - Nasdaq
Moleculin reports Annamycin cancer drug synergy at AACR meeting By Investing.com - Investing.com UK
Moleculin Announces New Pre-Clinical Data for Annamycin - GlobeNewswire
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Groundbreaking Cancer Drug Data: Annamycin Demonstrates Effectiveness Against Multiple Cancer Types - Stock Titan
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - ADVFN
Moleculin Biotech Releases Corporate Presentation Online - TipRanks
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt
Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus
Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire
Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan
Moleculin Announces Acceptance of Abstract to be Presented at th - GuruFocus
Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia
Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):